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Abstract
Background: Insulin-like growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) are among the most
promising growth factors for promoting cardiorepair. Here, we evaluated the combination of cell- and gene-based
therapy using mesenchymal stem cells (MSC) genetically modified to overexpress IGF-1 or HGF to treat acute
myocardial infarction (AMI) in a porcine model.
Methods: Pig MSC from adipose tissue (paMSC) were genetically modified for evaluation of different therapeutic
strategies to improve AMI treatment. Three groups of infarcted Large White pigs were compared (I, control,
non-transplanted; II, transplanted with paMSC-GFP (green fluorescent protein); III, transplanted with paMSC-IGF-1/HGF).
Cardiac function was evaluated non-invasively using magnetic resonance imaging (MRI) for 1 month. After euthanasia
and sampling of the animal, infarcted areas were studied by histology and immunohistochemistry.
Results: Intramyocardial transplant in a porcine infarct model demonstrated the safety of paMSC in short-term
treatments. Treatment with paMSC-IGF-1/HGF (1:1) compared with the other groups showed a clear reduction in
inflammation in some sections analyzed and promoted angiogenic processes in ischemic tissue. Although cardiac
function parameters were not significantly improved, cell retention and IGF-1 overexpression was confirmed
within the myocardium.
Conclusions: The simultaneous administration of IGF-1- and HGF-overexpressing paMSC appears not to
promote a synergistic effect or effective repair. The combined enhancement of neovascularization and fibrosis
in paMSC-IGF-1/HGF-treated animals nonetheless suggests that sustained exposure to high IGF-1 + HGF levels
promotes beneficial as well as deleterious effects that do not improve overall cardiac regeneration.
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Background
Despite the effectiveness of current treatments, which
have greatly reduced short-term morbidity and mortality
of acute myocardial infarcted patients [1, 2], they are
unable to prevent cardiac degeneration due to massive
tissue damage. The gold standard technique is heart
transplant, a complex surgery with serious limitations,
including donor shortage and possible rejection, which
prompts the search for therapeutic alternatives.
Cell therapy and regenerative medicine have raised
great expectations in recent years [3]. Initially, an autolo-
gous myoblast grafting trial concluded that they did not
integrate into the host myocardium or transdifferentiate
into cardiomyocytes, despite confirmation of some bene-
ficial effects on myocardial function [4]. More recent
studies suggest that skeletal muscle-derived stem cells
(naive, preconditioned, or genetically modified) have the
ability to adopt a cardiomyocyte phenotype in vitro and
in vivo [4, 5]. Stem cells are now being assessed as a
therapeutic tool in the treatment of ischemic heart dis-
ease, with some promising initial results. These studies
attempt to minimize the evolution of damaged tissue
after acute myocardial infarction (AMI) and promote re-
pair of affected cardiac structures [6, 7]. In murine
models, adult stem cell transplant in the heart leads to
improved cardiac function and neoangiogenesis [8, 9].
Cell therapy is thus an alternative strategy whose main
objective is to repair damage and/or delay its evolution
after ischemic stroke.
These promising initial findings led to the develop-
ment of numerous clinical trials of cardiac cell therapy.
Results have confirmed the safety of these procedures,
especially when autologous cells are used. Currently,
more than 850 clinical trials for cardiovascular disease
have been conducted, and more than 60 are specific for
AMI treatment [10]. Whereas most use mesenchymal
stem cells (MSC) from bone marrow (BM-MSC), some
use MSC obtained from adipose tissue or from umbilical
cord, and even cardiac stem/progenitor cells (CSC/CPC).
For example, the phase I completed APOLLO clinical trial
used adipose tissue-derived stem cells [11] and the
TECAM2 clinical trial used hematopoietic stem cells to
treat AMI [12]. Administration routes differed in each of
these; in the latter, treatment was administered by intra-
coronary injection, whereas APOLLO used a device called
NOGA™ (cardiac mapping system) to allow transendocar-
dial cell administration.
The concept of the heart as a post-mitotic organ in-
capable of self-renewal has changed in recent years.
Early studies showed that some cardiomyocytes can re-
enter the cell cycle [13, 14] and lead to limited regener-
ation [13, 14]. A possible stem cell population was soon
identified in the adult rodent heart, whose regeneration
potential was analyzed in animal models of AMI [15]. In
many studies, this population of CSC/CPC is the main
objective as an alternative to other stem cell types used
to date. Only three clinical trials have used CSC (SCIPIO,
CADUCEUS, and TICAP), with promising results [16–18].
Based on very promising preclinical results, an additional
phase I/IIa clinical trial (CARE-MI) was recently launched,
in which 55 patients are being treated with allogeneic CSC/
CPC (EudraCT 2013-001358-81).
The therapeutic capacity of CSC/CPC is attributed
mainly to their potential to differentiate into many distinct
reparative cell types. There is nonetheless insufficient
documentation of efficient differentiation of transplanted
CPC into therapeutically relevant numbers of functional
reparative cells in injured tissues [19]. Low survival ap-
pears to be one of the main factors, although limited
availability of functional niches and deficient early
vascularization could also be responsible. A substantial
part of these repair effects might not be mediated
mainly by direct differentiation of engrafted CPC, but
rather by CPC-secreted paracrine factors [20]. These
factors are postulated to promote survival and arterio-
genesis [21], protect against myocardial ischemia, and
stimulate endogenous repair and regeneration path-
ways, resulting in durable benefits despite evanescent
survival of transplanted cells [22].
Several reports suggest that various stem cell-secreted
substances, such as growth factors, mediate angiogenesis
and protect against myocardial ischemia. Some studies
showed the angiogenic and anti-apoptotic properties of
hepatocyte growth factor (HGF) [23], and insulin-like
growth factor-1 (IGF-1) has cardioprotective properties
and beneficial effects on the heart [24]; this role in myocar-
dial repair has led to their therapeutic evaluation. IGF-1
and HGF are a good option to be considered for such ther-
apies, and their direct administration has been evaluated
for potential AMI treatment in porcine models [25].
Another strategy in treatment for cardiac regeneration
combines cell and gene therapy to enhance their efficacy.
Many studies have been performed to improve the effect-
iveness of cardiovascular therapy using a variety of popula-
tions, including CSC and cardiomyocyte progenitors
genetically engineered using the αMHC promoter [26]. Al-
though the effects of administering different cell types or
growth factors, separately and independently, have been
analyzed [27, 28], few studies have examined their com-
bined effect [29]. Here, we explored the combination of
cell and gene therapy strategies using MSC genetically
modified to overexpress IGF-1 or HGF growth factors as a
single treatment in a porcine AMI model.
Methods
Cell culture and gene modifications on paMSC
The isolation of pig MSC from adipose tissue (paMSC)
from lipoaspirates of pigs was carried out according to
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previous MSC isolation protocols in humans [30, 31]
and pigs [32, 33]. Briefly, ventral adipose tissue was
washed twice with phosphate-buffered saline (PBS) and
was subjected to enzymatic digestion at 37 °C for 1 h
with collagenase V (Sigma; 0.075 % final concentration).
Digested tissue was centrifuged at 450 g for 10 min, and
the cell suspension was filtered through two layers of
nylon chiffon (70 μm mesh). paMSC were plated (5 × 103
cells/cm2) and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum (FBS), 1 % L-glutamine and 1 % penicillin/strepto-
mycin solution (37 °C, 5 % CO2). After 7 days, and when
cultures had reached a confluence of approximately 80 %
(passage 0), cells were trypsinized (0.05 % Trypsin–EDTA;
Invitrogen) and seeded at a density of 5 × 103 cells/cm2
(passage 1). In some experiments, growth was compared
in distinct O2 conditions (20 % vs 3 % O2).
paMSC-IGF-1-green fluorescent protein (GFP)- and
paMSC-HGF-Cherry were generated by stable trans-
duction with lentiviral vectors encoding IGF-1-GFP
(pRRLsin18.CMV-IGF-1-IRES-GFP) or HGF-Cherry
(pRRLsin18.CMV-HGF-IRES-Cherry) sequences.
Cell and molecular characterization of MSC
The International Society for Cellular Therapy (ISCT)
has defined the minimal criteria to be met by cells to be
considered MSC as the following [31]: adherence to
plastic in standard culture conditions; positive pheno-
type: CD105, CD73, CD90 and negative phenotype:
CD45, CD34, CD14 or CD11b (monocytes), CD79a or
CD19 (lymphocytes); and in vitro differentiation to three
mesoderm lineages: osteocytes, adipocytes and chondro-
cytes (demonstrated by staining of in vitro cell culture).
All experiments were carried out in at least four cell
isolations. The morphological evaluation of cells was
performed by direct observation with a microscope
(Nikon Eclipse TE-2000-S) and photographic record
digital camera (Nikon DS-Fi1).
Flow cytometry
Phenotypic analysis was performed by FACS (fluores-
cence-activated cell system). The antibodies used were
CD90-FITC, CD105-FITC, CD44-FITC, CD29-FITC,
CD31-FITC, and CD45-FITC. Mouse IgG1-FITC, mouse
IgG2a-FITC, and rat IgG1-FITC were used as isotopic
controls. After incubation, cells were washed with PBS
(300 g, 5 min). Quantitative analyses were performed
using a flow cytometer FACS Scan (BD Biosciences, CA,
USA), as previously described [33].
The FACS technique was used to separate paMSC
transduced with GFP which were not infected (group II).
This technique was also used to separate the same cells
transduced with pRRLsin.18.CMV-IGF-1-IRES-GFP or
pRRLsin.18.CMV HGFIRES-Cherry vectors of negative
cells in these transductions (group III; flow cytometer
FACS Aria; BD Biosciences).
paMSC in vitro differentiation
The pluripotency determination was carried out using
cell differentiation assays into three lineages (adipocytes,
chondrocytes, and osteocytes), as previously described
[33]. We performed more than three independent sets of
experiments.
Molecular studies of gene expression were performed
with adipogenic differentiation markers (PPAR-γ and
LPL) and osteogenic markers (RUNX-2, BMP-2, BMP-6,
GATA-4, COL1A1, and BGLAP, which is equivalent to
human osteocalcin) whose expression and/or activation
is required for the commitment and progression of each
particular differentiation pathway. In this analysis, RNA
was extracted from all studied samples. As negative con-
trols, cells grown in standard culture medium were used
and, for test samples, the cells were grown in specific
differentiation media for each test. These cDNA were
amplified by reverse transcription polymerase chain reac-
tion (RT-PCR) to examine differences in gene expression
of markers involved in each differentiation [32].
Karyotype and population doubling (PD) measure
After culture, 0.1 μg/ml colcemid was added for 4 h and
metaphase cells were prepared by standard methods. Q-
FISH was carried out using a FITC-labeled LL(CCCTAA)3
PNA telomeric probe (Eurogentec, Liège, Belgium) as
described [34]. Cumulative PD was calculated with the
formula PD = (log (Nn/Nn_1))/log 2 (n: passage; N: cell
number).
RT-qPCR
Total RNA was extracted from the different cell prepara-
tions (mature cells, induced, and control samples) using
TRI REAGENT (Sigma-Aldrich) according to the manu-
facturer’s instructions. The total RNA concentration and
purity was determinate using a Nano-Drop spectrophotom-
eter (Thermo Scientific), and the 260/280 ratio generally
ranged between 1.9 and 2.0 cDNA was synthesized from
1 μg of total RNA using random primers (Invitrogen) and
SuperScript® III Reverse Transcriptase (Invitrogen) accord-
ing to the manufacturer’s instructions. Primer sequences
are listed in Additional file 1 (Table S1) and were designed
using the web program of the National Center for Biotech-
nology Information (NCBI). The quantitative RT-PCR
(RT-qPCR) was performed using SYBR Green (Applied
Biosystems) in a Mastercycler® ep realplex (Eppendorf ).
RT-qPCR products were quantified using the 2–ΔΔCt
method, using GusB as ACTB as housekeeping genes
(indicated in each analysis).
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Lentiviral vector transduction of paMSC
Lentiviral vectors were produced by transient calcium-
phosphate transfection of 293T cells as previously de-
scribed [35], and viral stocks with titers (transduction
units; TU/mL) of 1–2 × 107 TU/ml were prepared.
To generate paMSC-IGF and paMSC-HGF cells,
paMSC were stably transduced (multiplicity of infection
(MOI) = 50) with lentiviral vectors encoding IGF-1-
GFP or HGF-Cherry. Lentivirus was added together
with 8 μg/ml polybrene (Sigma, St Louis, MO, USA) in
expansion medium for 12 h at 37 °C; fresh medium was
added the next day, and culture maintained for 4–5 days.
Transduced paMSC were sorted by GFP or Cherry fluor-
escence. Control transductions were conducted with
empty vectors (pRRL-GFP or pRRL-Cherry).
Immunocytochemistry
Immunohistochemistry was performed by standard
methods. Primary and secondary antibodies used are
listed in Additional file 2 (Table S2). Incubation with
secondary antibody alone did not produce any detectable
background signal. Slides were mounted in Hoechst
33342 (Invitrogen, Eugene, Oregon, USA), Vectashield
with DAPI (Vector labs) or Prolong® Gold Antifade with
DAPI (Invitrogen) and analyzed by confocal microscopy
(Leica SP5, Leica). GFP+ cells in the myocardium were
detected by immunohistochemistry with an anti-GFP
antibody (see Additional file 2: Table S2) and a secondary
antibody Alexa Fluor 568.
In vivo studies
The study protocol was approved by the Jesús Usón
Minimally Invasive Surgery Centre Animal Care and Use
Committee and according to the European Agreement
of Vertebrate Animal Protection for Experimental Use
Guide (86/609). All procedures were performed as de-
scribed [32], with indicated specific modifications.
Fourteen 3- to 4-month-old female Large White pigs
(Sus scrofa) (39 ± 9.72 kg) were subjected to experimental
AMI (distributed as one control animal without AMI and
injected with superparamagnetic iron oxide (SPIO)-labeled
GFP+ cells, an infarcted animal injected with the same
(SPIO)-labeled cells and four animals with AMI in each of
three treatment groups). Allogenic cell transplantation was
performed the same day of the infarction by intramyo-
cardial administration. A single dose (50 × 106 viable
cells/animal; n = 4 per group) was administered in a
maximum volume of 1.5 ml saline. Thus, cell transplant-
ation was performed using several injections (7–8 injec-
tions) in a volume of 0.2 ml of diluted cells (about 8 × 106
cells per injection) distributed surrounding the infarction
area. Group II received paMSC-GFP (50 × 106 cells/animal),
and group III received a combination of paMSC-IGF-1-
GFP and paMSC-HGF-Cherry (each 25 × 106 cells/animal);
these animals were compared with controls infarcted
but untreated with any cell type (control; group I). Pigs
were evaluated by magnetic resonance imaging (MRI)
before surgical intervention (T1, at baseline), and after
48 h (T2), with further studies at day 15 (T3) and day 30
(T4), prior to euthanasia and necropsy sampling. Left ven-
tricular ejection fraction (LVEF), cardiac output (CO),
stroke volume (SV), and infarcted area were measured.
After 1 month, pigs were euthanized with an intravenous
injection of potassium chloride solution (1–2 mmol/kg) to
obtain samples for histological analysis.
Analytical methods
To determine plasma concentrations of cardiac troponin I
(cTnI), myocardial creatinine kinase (CKMB), and myoglo-
bin levels, blood samples were collected at baseline, 48 h,
and 15 and 30 days after AMI induction. After centrifuga-
tion, cardiac enzymes were measured by commercially
available immunometric assays in a fluorometric immuno-
assay analyzer (AQT90 FLEX; Radiometer Medical ApS,
Brønshøj, Denmark).
MRI studies
Cardiac MRI was performed before the creation of the
model (baseline), and at 48 h, 15 and 30 days after infarct
induction and treatment using a 1.5 T MR system (Intera
1.5 T; Philips Medical Systems, Best, The Netherlands).
All imaging was performed under general anesthesia using
retrospective cardiac gating, with the animal in sternal de-
cubitus and a four elements phase array coil placed
around the animal’s chest. Images were acquired as previ-
ously described [32]. MR images were analyzed for left
ventricular volume, mass, function, and infarct size.
Histological analysis
Immediately after animal euthanasia, 1 month after AMI,
samples were obtained from the infarction area (named as
Heart 2, Heart 4, LV, and interventricular septum (IVS))
close to where the cell transplantation was performed and
the hematoxylin/eosin (H/E) and Masson’s trichrome
stainings were performed for the primary histological
examination in 5-μm paraffin-embedded tissue sections.
Inflammation, fibrosis, and new vessel formation were
analyzed in H/E studies. The values presented corres-
pond to the average obtained from each animal in each
group (n = 4). The values assigned are: for inflamma-
tion, 0 when it was absent, 1 mild, 2 light, 3 moderate,
and 4 severe; the presence of areas of fibrosis was set to
0 when the injury was not observed, 1 when its size
was below 5 % of the sample, 2 between 5 and 30 %, 3
between 30 and 60 %, and 4 when greater than 60 %;
neovascularization, value of 0 (none), 1 (few new ves-
sels found), 2 (mild), 3 (moderate), and 4 (numerous
new vessels).
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Immunohistochemistry
Pig heart paraffin-embedded sections were deparaffinized,
rehydrated, washed with PBS, and antigens were retrieved
with sodium citrate. For tyramide amplification, slides
were incubated with 0.3 % H2O2. Tissue sections were
then blocked and incubated overnight at 4 °C in blocking
solution with primary antibody IGF-1 (Santa Cruz Bio-
technology). Slides were washed and incubated for 1 h at
room temperature with secondary antibodies conjugated
to horseradish peroxidase (HRP) (see Additional file 2:
Table S2). Incubation with secondary antibody alone did
not give any detectable background signal. Vectastain
ABC kit Elite PK-6101 (Vectorlabs) was used to develop
DAB colorimetric assay.
Western blot
paMSC cells were lysed in RIPA buffer containing prote-
ase inhibitors (Roche) and, after centrifugation, the super-
natants were collected and protein quantified using the
DC protein assay (Biorad). Protein (30 μg/lane) was loaded
on 10–12 % SDS-polyacrylamide gels (Biorad) and West-
ern blotting was performed. The membranes were blocked
and incubated overnight with primary antibodies (see
Additional file 2: Table S2) diluted in 5 % non-fat milk in
PBS, 0.1 % Tween 20 (Sigma). Membranes were incubated
with the corresponding HRP-conjugated secondary anti-
bodies (see Additional file 2: Table S2) and developed with
HRP SuperSignal® West Pico Trial (Thermo Scientific).
Statistical analysis
Data are shown as mean ± SD. Non-parametric Kruskal-
Wallis and Mann-Whitney tests were used to compare
differences between groups for histological variables.
Two-way analysis of variance (ANOVA) and Tukey’s tests
were used in multiple comparisons for the remaining vari-
ables analyzed (cardiac enzymes and hemodynamic data).
Values of p ≤ 0.05 were considered significant. All statistical
computations were performed using SPSS 22.0 (IBM SPSS)
and GraphPad Prism® 6.0.
Results
Growth characteristics and phenotypic and molecular
characterization of primary paMSC
paMSC were isolated and expanded (passages 2–5) to
obtain primary cultures (see Methods) and were charac-
terized by flow cytometry. Immunophenotype analysis of
the different paMSC subpopulations confirmed similarity
with MSC from human and murine origins and matched
ISCT criteria: cells were positive for CD90, CD105, CD29,
and CD44, and negative for CD45 and CD31 (data not
shown), as previously described [31].
To determine whether oxygen concentration influ-
enced paMSC growth and function, as shown for human
MSC [36], we established paMSC cultures (5 × 103 cells/
cm2) and compared growth rates at 20 % and at 3 % pO2
over 15 passages. paMSC cultures at high and low O2
concentrations showed similar growth rates, which were
slightly higher for cells at 20 % pO2 (Fig. 1a). The
paMSC karyotype was similar to that of the domestic pig
(2n = 38) and relatively similar to human haMSC when
both were grown under 20 % pO2 conditions (Fig. 1b).
To demonstrate paMSC pluripotency, we performed
classical differentiation studies using three mesoderm
cell lineages: adipocytes, chondrocytes, and osteocytes
(Fig. 1c). In addition, semiquantitative RT-PCR con-
firmed an increase in most analyzed genes associated
with the specific differentiated cells, including peroxisome
proliferator-activated receptor γ (PPAR-γ) and finding sta-
tistically significant differences with lipoprotein lipase
(LPL) in adipogenic differentiation. These changes were
statistically significant in the case of collagen type I alpha
1 (COL1A1), RUNX-2, and BMP2/6 in osteogenic dif-
ferentiation (Fig. 1d); ACTB (β-actin) was used as the
reference gene.
Cellular and molecular characterization studies con-
firmed the similarity of porcine MSC with human and
murine MSC [37–39], and our unpublished results. The
studies suggested that paMSC growth is more resistant
to oxidative stress than such cells in other species.
Genetic manipulation of paMSC for IGF-1 or HGF
overexpression
Our main aim was to test the effect of sustained IGF-1
and HGF co-administration in an in vivo porcine infarc-
tion model. We used pRRLsin18.CMV-IGF-1-IRES-GFP
(paMSC-IGF-1-GFP) and pRRLsin18.CMV-HGF-IRES-
Cherry (paMSC-HGF-Cherry) lentiviral vectors (see
Additional file 3: Figure S1A) to transduce paMSC, thus
inducing co-expression of GFP and IGF-1 or Cherry and
HGF, respectively. paMSC transduction was optimized
with the empty control vector pRRLsin18.CMV-IRES-GFP
(gfp) for effective expression without inducing apparent
deleterious effects. Transduced paMSC, paMSC-IGF-1-
GFP (see Additional file 3: Figure S1B), in general referred
to as paMSC-mod, showed a similar behavior and were
easily purified by cell sorting (>90 %); an MOI of 50 was
used for further work. No influence of pO2 on either
transduction efficiency or the subsequent paMSC-GFP
sorting and expansion were observed (see Additional file 3:
Figure S1C).
MSC manipulation was monitored by comparison
with transduced HEK293 cells (control) as a reference.
paMSC-IGF-1-GFP cells showed a specific increase in
IGF-1 expression (see Additional file 4: Figure S2A-Vi)
with basal HGF expression (see Additional file 4: Figure
S2B-ii(MSC)). paMSC-HGF-Cherry cells showed specific
enhancement of HGF expression (see Additional file 4:
Figure S2B-Vi), with no increase in IGF-1 expression (see
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Additional file 4: Figure S2A-ii(MSC)). paMSC-IGF-1-
GFP and paMSC-HGF-Cherry cultures were purified, and
IGF-1 and HGF expression monitored by immunocyto-
chemical staining for markers and controls in positive-
and negative-sorted fractions (Fig. 2a and b; see Additional
file 5: Figure S3); Fig. 2a shows the GFP-positive (+) frac-
tion obtained after paMSC-IGF-1-GFP sorting, with ana-
lysis of the GFP-negative (–) fraction (see Additional file 5:
Figure S3A). The results obtained were similar to those
of paMSC-HGF-Cherry cells, with analysis of the
Cherry-positive (+) fraction, which showed enhanced
HGF expression (Fig. 2b) and of the Cherry-negative
(–) fraction, which demonstrated basal HGF levels
(see Additional file 5: Figure S3B). Comparative ana-
lysis of paMSC-IGF-1-GFP cells with unmodified
paMSC, paMSC transduced with empty vector
(paMSC-GFP), and paMSC-HGF-Cherry cells showed
a significant IGF-1 overexpression that correlated with
GFP expression (p ≤ 0.05). paMSC-HGF-Cherry cells
showed basal IGF-1 levels and significant differences
in IGF-1R levels compared with paMSC-IGF-1-GFP
(p ≤ 0.05) (Fig. 2c). Reverse analysis showed similar
Fig. 1 a Cell proliferation in distinct O2 conditions. Accumulated population doubling (PD) in a representative pig mesenchymal stem cells from
adipose tissue (paMSC) cell isolate (n = 2) at low (3 % O2, pink line) and conventional oxygen tension (20 % O2, blue line). Cumulative PD was
calculated with the formula PD = (log (Nn/Nn_1))/log 2 (n = passage; N = cell number). b Comparative karyotype in porcine and human MSC from
adipose tissue. Karyotype of paMSC cultured at 20 % O2 (B1) compared with hMSC cultures at 20 % O2 (B2). Porcine karyotype (2n = 38) showing
two sex chromosomes and 18 autosome pairs. c In vitro differentiation capacity of paMSC. Representative images showing in vitro paMSC
differentiation under phase contrast and DIC (differential interference contrast) microscopy. Oil Red O (C1, C2), Alcian Blue (C3, C4), and Alizarin
Red S (C5, C6) stainings of paMSC treated with control (C1, C3, C5) or adipogenic (C2), chondrogenic (C4), and osteogenic (C6) differentiation
media. Scale bars = 100 μm and 20 μm (C2). d Semiquantitative RT-qPCR of marker genes in paMSC after adipogenic and osteogenic differentiation.
Fold expression of adipogenic and osteogenic markers after quantitative experiments of adipogenic and osteogenic lineages (n = 4). ACTB was used as
the endogenous gene. paMSC (–) correspond to cells grown with standard medium; paMSC (+) to cells grown in the specific differentiation medium.
*p≤ 0.05; **p≤ 0.001
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Fig. 2 (See legend on next page.)
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results; no alterations were found in c-MET (HGF re-
ceptor) expression in any cell population (not shown).
Western blot analysis confirmed weak but clear HGF
overexpression in paMSC-HGF-Cherry cells (Fig. 2d),
but did not confirm IGF-1 expression, probably due to
inappropriate antibodies for the pig (not shown). Re-
sults indicated that IGF-1 is selectively overexpressed
in paMSC-IGF-1-GFP; we also observed a significant
reduction (p ≤ 0.05) in the IGF-1 receptor (Fig. 2c).
paMSC viability after labeling for in vivo MRI detec-
tion was tested by cell count analysis using Trypan Blue,
which showed no differences between unlabeled and
SPIO-labeled cells in any subpopulation (Fig. 3a). Fur-
thermore, to confirm maintenance of basal gene expres-
sion profiles after expansion, we used RT-qPCR to study
a selected panel of genes in all paMSC-mod cells and
controls immediately before transplant (Fig. 3b). Although
some variation was observed, we confirmed much higher
IGF-1 expression in paMSC-IGF-1-GFP cells (p ≤ 0.0001).
As in paMSC-GFP cells, this group also showed GFP ex-
pression. paMSC-HGF-Cherry cells showed higher Cherry
expression, absent in the remaining populations. ACAN
(aggrecan), MYH7 (myosin heavy chain 7), MEF2C
(Myocyte Enhancer Factor 2C) (p ≤ 0.05) and HGFL
(Hepatocyte Growth Factor-Like Protein) levels were
increased compared with other populations. Only small
differences were found in expression of the primitive
cell marker KIT, with higher levels in non-transduced
cells than in cells transduced with IGF-1 or HGF;
paMSC-GFP cells expressed lower KIT levels. RUNX2,
VEGFA (p ≤ 0.0001), LPL and SOD2 levels were also in-
creased in paMSC-GFP cells (Fig. 3b).
Effects of paMSC-mod transplantation in a porcine model
of AMI
Using an in vivo porcine myocardial infarction model,
we analyzed the effectiveness for cardiac repair of heter-
ologous paMSC previously transduced for HGF or IGF-1
overexpression (paMSC-mod). Figure 4a summarizes the
overall experimental design used to compare the potential
therapeutic effects of paMSC-mod in vivo in three experi-
mental groups: group I (control), group II (paMSC-GFP),
and group III (paMSC-IGF-1 and -HGF).
Infarct size was estimated in all groups 48 h post-AMI
(see Additional file 6: Figure S4A). Plasma levels of the
infarct markers TnI (troponin) and myoglobin were
clearly increased from T1 to T2 in all treatment groups
compared with controls, with a maximum in group III
of 20 μg/l TnI (see Additional file 6: Figure S4B) and
250 μg/l myoglobin (see Additional file 6: Figure S4C).
These T2 plasma levels were reduced at T4 to nearly
basal levels (data not shown). Plasma levels of the infarct
marker CKMB varied greatly among groups, even at T1
(see Additional file 6: Figure S4D) and at the 1-month
(T4) follow-up.
Functional measurements revealed that LVEF was de-
creased significantly (p ≤ 0.05) 48 h post-AMI with respect
to baseline levels. In addition, stroke volume inversely cor-
related with heart rate evolution within all groups and car-
diac output was not altered between groups (Fig. 4b).
These data suggested that all animals in each experimental
group sustained similar cardiac damage and that differ-
ences were evident by 48 h after AMI induction. Further-
more, a significant retention of paMSC-mod cells was
demonstrated by cardiac MRI. Figure 4c shows the long-
axis view of T2-star CMR images of a control-MI repre-
sentative animal and another similar to group II, paMSC-
GFP-transplanted, but labeled with SPIO. paMSC engraft-
ment within the infarcted myocardium were observed at
any analyzed time-point, confirming cell retention and
survival, 1 month after transplant.
T2 short-axis delayed enhancement images summariz-
ing infarct size evolution for all groups are shown in
Fig. 5a. Images from the first 15 days post-AMI induc-
tion (T2 and T3) show gradual reduction of the IVS
closer to the apex, mainly in the control group and
group III, with clear reduction of the ventricular wall. At
1 month (T4), although recovery from lesions was not
complete, all groups showed a slight improvement in af-
fected areas, with images similar to baseline in some
cases (control group and group II).
After treatment, parameters improved over time, with
similar levels in treated groups. At 1 month, the percent-
age of recovery, calculated by comparing the LVEF in T4
with T2, was higher in controls (group I, 11.77 %) and
group II (8.43 %) than in group III (2.34 %) (Fig. 5b).
Comparison of cardiac output and stroke volume showed
(See figure on previous page.)
Fig. 2 Insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF) overexpression in pig mesenchymal stem cells from adipose tissue
(paMSC) after lentiviral transduction. a α-IGF-1 immunocytochemistry in paMSC transduced with the pRRLsin18.CMV-IGF-1-IRES-GFP lentiviral vector
(positive fractions). Negative controls (–) show evaluation of Cherry + cells; scale bars= 20 μm. b α-HGF immunocytochemistry in paMSC transduced
with the pRRLsin18.CMV-HGF-IRES-Cherry lentiviral vector (positive fractions); analysis was performed after cell separation. Negative controls (–) show
evaluation of green fluorescent protein (GFP) + cells; nuclei were DAPI-stained; scale bars= 20 μm. c Relative expression of selected markers and genes
to characterize paMSC-mod cells. IGF-1, IGF-1R, GFP, and Cherry expression relative to the endogenous GusB gene in the cell populations (n = 2;
*p ≤ 0.05). d Western blot analysis of HGF in several cell populations transduced with the pRRLsin-18.CMV-HGF-IRES-Cherry vector. HEK293T
cell lines were used as a control; α-tubulin was used as a loading control
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some similarities (Fig. 5b). The control group showed a
reduction in both values in T2 relative to T1, which im-
proved relative to basal values in T3. In the last 15 days of
the study, these values stabilized and decreased slightly,
but were still above baseline levels (T1); Fig. 5c shows
mean values for all groups at all times of analysis (T1–T4).
The evolution of cardiac output and stroke volume for
group II (paMSC-GFP-injected) was generally similar to
the other groups throughout the study, with a difference
in T4 in which values improved further compared to T3.
The evolution of cardiac output was similar in group III
(paMSC-IGF-1/HGF) to the other groups, with improved
stroke volume in T4 compared to T3, as for group II.
Heart rate values varied considerably in all treated groups
throughout the experiment, although it was generally
lower after 1 month (T4) compared to basal levels (T1)
(Fig. 5b); this parameter increased moderately in controls
(group I), with slight differences compared to basal levels.
Although statistical analysis showed no significant differ-
ences in any of the parameters analyzed, MRI allowed
straightforward follow-up of changes in cardiac pathology
for all groups (Fig. 5c).
Infarcted area measurements after AMI showed values
for damaged areas at T2 ranging from 7.8 to 13 %, with
the largest infarcts in the control group and group III
(Fig. 5d). All groups showed a gradual reduction in the
percentage of infarcted areas. Kinetics and reduction of
infarcted area were similar in group II and the control
group (~5 %); recovery kinetics was slower in group III
animals, which maintained a larger infarcted area (9.7 %)
than other groups (Fig. 5d).
As treatment of infarcted pigs with IGF-1- and HGF-
overexpressing paMSC had no apparent effect on func-
tional recovery, we tested for paMSC-GFP+ cells in post-
euthanasia samples (T4). In a positive control animal
(paMSC-GFP + SPIO transplanted but not infarcted),
GFP+ cells were present and stained yellow-orange (see
Additional file 7: Figure S5A), with no signal in nega-
tive controls (see Additional file 7: Figure S5B). We
evaluated these cells in samples from animals from
each group and observed GFP+ cells in group II and III
(Fig. 6a; see Additional file 8: Figure S6); these cells ap-
peared in clumps and were not isolated, as in the control
transplanted, no infarcted pig (see Additional file 7: Figure
S5A and see Additional file 9: Figure S7B). Molecular
studies (genomic PCR) of cardiac tissue showed GFP-
positive cells in a Heart 2 sample from the infarcted ani-
mal with paMSC-GFP, labeled with SPIO (see Additional
file 9: Figure S7A). In addition, we also confirmed IGF-1
overexpression (detected by DAB immunohistochemistry)
in group III samples (Fig. 6b).
Evaluation of inflammation, fibrosis, and
neovascularization in paMSC-mod-transplanted pigs after
AMI
Results derived from anatomopathological evaluation of
myocardial sections are summarized in Fig. 6c. Samples
from myocardium, Heart 2, Heart 4, LV, and IVS of ani-
mals from each group (n = 4) are shown. LV samples were
used as the reference control in each animal, as this re-
mote myocardial region is not damaged by infarction or
cell transplant. Statistical analyses showed no significant
differences in each section among groups (Kruskal-Wallis
test); comparison, however, of all sections within each
group (Mann-Whitney test) indicated significant differ-
ences in all parameters analyzed. In this figure it should
be noted that a moderate-low or negative (group III) in-
flammation was found in Heart 2 samples, while the rest
of the sections analyzed showed similar levels to the other
groups (i.e., IVS; group III). This is the clearest difference
between groups II and III. Fibrosis events (see the score
definition in the Methods section) were found in groups II
and III; these were clearest in Heart 2 sections, followed
by IVS sections, and negative in LV (Fig. 6c).
Large dystrophic calcification areas were observed in
three animals, two in Heart 2 sections and one in IVS
(group II; Fig. 6D1 and D3). Group III pigs had more
damaged areas than other groups, especially fibrosis in
Heart 2 and IVS samples. Fibrosis was pronounced in
Heart 2 sections from three of four animals and two of
four IVS sections; it was moderate in other sections, and
mild in one (LV). This group showed fibrosis even in the
Heart 4 section, whereas it was barely observed in Heart
4 samples from most animals in other groups (only
group II, animal 1).
Interestingly, groups II and III demonstrated an in-
creased and similar (almost parallel) pattern of fibro-
sis and neovascularization in the different regions
analyzed, especially evident in Heart 2 samples. This
correlation was less clear for inflammation, although
group III animals showed multifocal granulomas
(Fig. 6E2) that were larger in fibrotic areas, with
(See figure on previous page.)
Fig. 3 a Effect of superparamagnetic iron oxide (SPIO) labeling in pig mesenchymal stem cells from adipose tissue (paMSC) viability. paMSC were
transduced with pRRLsin.18.CMV-IRES-GFP or were mock-transduced. Both populations were SPIO-labeled (day 0), followed by weekly trypan blue
exclusion analysis for 1 month. paMSC mock-transduced (left panel) or paMSC-transduced cells (right panel); SPIO-labeled cells (pink lines) in comparison
with mock cells (blue lines). Results are shown as viability (%). b RT-qPCR gene expression profile of transduced paMSC. paMSC populations were
analyzed by RT-qPCR at similar passages (n = 2). For those used in the in vivo evaluation, results are shown as the mean of all values. Color
scale indicates relative expression values
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many new blood vessels; group III animal 2 also had
moderately sized dystrophic calcification areas
(Fig. 6E1) and cartilaginous metaplasia areas in IVS
(Fig. 6E3).
Overexpression of IGF-1 and HGF via paMSC promoted
neoangiogenesis and reduced inflammation in some heart
sectors, although they were not proportional to values for
cardiac function recovery.
Discussion
Adipose tissue-derived MSC (haMSC) are considered a
promising stem cell type given the abundance of stem
(See figure on previous page.)
Fig. 4 a Experimental design for the in vivo study. Black arrows indicate MRI monitoring, at which time blood samples were obtained for
analytical determinations. b T1 vs T2 cardiac function studies. Analysis of cardiac function parameters (left ventricular ejection fraction (LVEF),
cardiac output (CO), stroke volume (SV) and heart rate (HR)), comparing T1 and T2 for each group (*p ≤0.05). c Cell localization by MRI. T2-star
CMR representative images in a long-axis view of a heart that received paMSC-GFP + SPIO cells vs the control group, at different time points.
T1, baseline before cell transplant; T2, 0–48-h follow-up; T3, 15 days; T4, 30 days. White arrows indicate SPIO-labeled cells. AMI acute myocardial
infarction, GFP green fluorescent protein, HGF hepatocyte growth factor, IGF-1 insulin-like growth factor-1, paMSC pig mesenchymal stem cells
from adipose tissue
Fig. 5 AMI evolution monitored by MRI. a Image sequence for a representative animal from each study group at the four follow-up times. Images
were taken on the short axis in the T2 format. b Cardiac function studies. Left ventricle ejection fraction (LVEF), cardiac output (CO), stroke volume
(SV), and heart rate (beats/minute) were analyzed. c Numerical data of cardiac function parameters and infarcted area. d Infarcted area evaluation.
This graph shows the results obtained (%) after analyzing the infarcted area by MR images during a month of monitoring. On the x axis for b and
c, 1, 2, 3, and 4 indicate follow-up times as described in Fig. 4c (*p≤ 0.05). GFP green fluorescent protein, HGF hepatocyte growth factor, IGF-1
insulin-like growth factor-1, paMSC pig mesenchymal stem cells from adipose tissue
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cells in this tissue, which has no donor limitation and is
easily available by low-invasive methods [40]. Results in
AMI treatment are modest, however, and the mecha-
nisms involved are still not fully understood [40, 41]. Re-
cent studies using two distinct cardiac stem cell (CSC)
populations showed encouraging results in early clinical
evaluation [16–18].
Survival, engraftment, and persistence of transplanted
cells or their progeny is extremely limited [42]. The
frequently reported moderate improvement in cardiac
function is thought to be produced by the liberation of
paracrine factors that mediate survival, neovascularization,
remodeling, and cell proliferation [43, 44]. Exosomes were
also shown to mediate many MSC functions [45], later ob-
served in CSC [46]. Analysis of the angiogenic potential of
MSC-secreted factors (conditioned medium) for direct
therapeutic use indicated a reduction in infarct size and
conservation of systolic and diastolic cardiac output,
which confirmed the value of these factors in counteract-
ing AMI. Finally, other studies have also demonstrated the
immunomodulatory properties of MSC that are related to
their capacity to migrate to injury sites and/or neovascu-
larize in ischemic areas, acting on different subsets of im-
mune cells [47]; this property has been potentiated using
genetically modified MSC [48].
Our initial studies of paMSC growth established appro-
priate conditions to obtain adequate cell doses for treat-
ments. Proliferation studies showed distinct behavior of
paMSC compared with human MSC grown at different
oxygen concentrations. In low oxygen conditions, human
MSC cultures showed significantly greater genetic stability
and higher yields [36, 49]; this was related to elevated oxi-
dative stress and DNA damage caused by growth at high
oxygen tension, which helped to accelerate senescence
[36, 50]. Results in the porcine model showed a similar
paMSC growth profile at low and high oxygen tension,
which suggests greater paMSC resistance to oxidative
stress than with human MSC. Genetic stability of paMSC
was confirmed in both oxygen conditions [51], and cells
maintained multipotent differentiation capacity. Some dif-
ferences were nonetheless observed in comparison with
haMSC, which suggested intrinsic biological differences
that could affect the therapeutic responses of paMSC vs
human MSC.
Post-AMI stimuli activate CSC mediated by paracrine
feedback between myocytes and the CSC. In response to
stress, myocytes produce growth factors and cytokines
for which CSC have receptors [25]. After demonstrating
that CSC respond to growth factors secreted by adjacent
myocytes, Urbanek et al. confirmed the efficiency of
combined recombinant IGF-1/HGF treatment in mice
and dogs [52]. CSC are activated in situ by local admin-
istration of IGF-1/HGF in a porcine heart infarction
model [53], which improved ventricular function in pigs.
Therefore, intracoronary administration of these factors
was proposed as a strategy to reduce post-AMI cardiac
remodeling and induce cardiac regeneration [25]. Finally,
direct IGF-1 + HGF administration was recently evalu-
ated in a porcine model of chronic myocardial infarction
(MI), in which growth factor delivery reduced pathological
hypertrophy, led to formation of new small cardiomyocytes,
and increased capillarization [54].
Priming (preconditioning) of MSC or co-administration
with growth factors is also used to augment therapeutic po-
tential. An IGF-1 +HGF combination loaded in polylactic-
co-glycolic acid microcarriers with haMSC enhanced
engraftment of the transplanted haMSC cells and
showed a 1.3-fold higher density of medium-sized blood
vessels in the infarct border zone [29]. hMSC precondi-
tioning with IGF-1 prior to transplant in infarcted rats in-
creased engrafted cell survival in the ischemic heart,
decreased myocardium cell apoptosis, and reduced inflam-
matory cytokines [55]. In most preconditioning strategies,
IGF-1 is also proposed as a mediator [56].
IGF-1 and HGF are thus being evaluated in different mo-
dalities of cardiac repair [43, 57], although the mechanisms
(See figure on previous page.)
Fig. 6 a Immunohistochemical detection of GFP+ paMSC in heart sections. Heart sections were analyzed from two group III pigs (Heart 2 section)
using Alexa 568-labeled anti-GFP (red) and DAPI (blue) counterstaining. Left, negative controls (DAPI alone) to establish tissue autofluorescence. Inset,
enlarged image from one animal (dotted area). b IGF-1 expression in myocardial sections of a representative group III pig. Left, anti-IGF-1 staining
developed with DAB immunohistochemistry in a representative section from a group III pig (paMSC-IGF- 1-GFP/HGF-Cherry). Right, negative
control (no anti-IGF-1). c Graphical representation of pathological studies on inflammation, fibrosis, and new vessel formation in the collection
of samples analyzed in all experimental groups studied. Values shown as the mean of various sections for each animal in each group (n = 4
animals/group; *p ≤0.05) (for criteria, see Methods). d Histological evaluation by H/E staining in group II pigs (paMSC-GFP+). Fibrosis is very
marked in this group, with calcification and granulomatous areas. (D1, D2) Heart 2 section, animal 2; (D3) Heart 2 section, animal 1, in which
we observed dystrophic calcifications surrounded by multinucleated giant cells. (D4) IVS section, animal 1 showed severe fibrosis accompanied by
neovascularization. (D1) Thick arrow: area of calcification; thin arrow: lymphoplasmacytic granuloma; (D2) lymphoplasmacytic granuloma; (D3)
thick arrow: area of calcification; thin arrow: giant cells; (D4) Arrows shows fibrosis. e Histological evaluation by H/E staining in group III pigs
(paMSC-IGF-1/HGF). (E1, E2) Heart 2 section, animal 2 showed numerous granulomas with calcification in the fibrotic area. (E3) IVS section;
animal 2 showed cartilaginous metaplasia. (E4) IVS section, animal 3, large areas of calcification and a severe fibrosis. (E1) Thick arrow: area of
calcification; thin arrow: granuloma. Around fibrosis; (E2) arrows show granuloma; (E3) arrows indicate the cartilaginous metaplasia; (E4) thick
arrow: area of calcification. The rest signals were assigned to fibrotic areas. GFP green fluorescent protein, HGF hepatocyte growth factor, IGF-1
insulin-like growth factor-1, IVS interventricular septum, LV left ventricular, paMSC pig mesenchymal stem cells from adipose tissue
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involved remain to be fully understood. Some studies
showed that HGF treatment post-AMI attenuates systolic
cardiac remodeling and cardiac dysfunction, with a cardio-
protective effect; these effects were linked to angiogenic
and anti-apoptotic mechanisms [58]. Evidence also im-
plicates IGF-1 in vascular protection, which might be
beneficial in chronic cardiac insufficiency [59] and in
treatment of sepsis-associated cardiac dysfunction [60].
Given the promising results with direct HGF and/or
IGF-1 administration [25, 54], several attempts have been
made to engineer MSC to vehiculate IGF-1 or HGF ex-
pression. Kouroupi et al. manipulated neural stem/precur-
sor cells (NPC) to overexpress IGF-1; using live-imaging
techniques, they reported that IGF-1 transduction en-
hanced the motility and tissue penetration of grafted NPC
[61], although no significant in vivo improvement was
demonstrated [62]. Human MSC and paMSC were trans-
duced with lentiviral vectors to overexpress IGF-1 [63];
overexpression of this gene improved induction by 5-
azacytidine and promoted limited cardiomyocyte-like
differentiation [63]. Experience is broader for genetic
manipulation of MSC to overexpress HGF. Early work
with rat BM-MSC showed decreased infarcted scar area
and increased angiogenesis in HGF-MSC-treated animals
[64]. In the porcine model, paMSC (alone or vascular
endothelial growth factor (VEGF)/HGF-transfected)
improved cardiac function and perfusion, probably by
increasing angiogenesis and reducing fibrosis; MSC +HGF
was superior to MSC +VEGF [65].
We used the porcine model to explore the synergistic
effect of combined, sustained administration of paMSC
modified individually to overexpress IGF-1 and HFG, la-
beled with fluorescent markers. This approach would
allow later adjustment of the balance between growth
factor supply by altering the ratio of the two paMSC
populations. We generated and validated optimized
lentiviral vectors and transduced paMSC, followed by
purification, by which we obtained enriched paMSC-
IGF-1-GFP and paMSC-HGF-Cherry cells that were
evaluated in vitro and in vivo. Results showed that the
cell doses used in the animals caused no toxicity or
short-term safety problems.
We found improvement in cardiac function (increases
in LVEF, cardiac output, and stroke volume, and reduction
in heart rate and infarction area) in all groups from day 15
(T3), although these changes were not statistically signifi-
cant in any case and were similar to non-paMSC-treated
infarcted controls (group I). Although intragroup variabil-
ity was marked, it did not appear to be the main reason
for these results. Overall results for treatment group III
pigs (paMSC IGF/HGF) were in fact poorer than those for
group II (paMSC-GFP; paMSC bearing the empty vector).
At termination of the in vivo experiment, the heart
apex and IVS showed fibrotic areas during macroscopic
assessment and sampling, and evaluation of infarction
degree by Masson’s trichrome staining showed a larger
proportion of affected areas in group III (see Additional
file 10: Figure S8), and these pigs had larger infarctions
than in other groups.
Although paMSC could not be identified in all samples,
immunohistochemistry and molecular assays confirmed
live paMSC in some group II and III tissues at 1 month
(T4) follow-up, which suggests that the functional results
are not due to elimination of paMSC-IGF- 1/HGF. Com-
parable results have been reported after autologous por-
cine BM-MSC implant for treatment of aortic injury [66].
Hematoxylin/eosin staining was used to evaluate the
degree of resolution of cardiac damage after each treat-
ment. The control group (I) had the lowest degree of
damage, mainly in Heart 2 and IVS samples, but pericar-
ditis was more severe compared with other groups and
lesions were visible in all sections. By contrast, group III
Heart 2 and IVS sections were the most affected by fi-
brosis and inflammation, followed by those of group II.
Angiogenesis was also more evident in sections from
group III than the other groups. We also found a correl-
ation between fibrosis and neovascularization, especially
in groups II and III.
Several factors could contribute to the lack of significant
differences. Kren et al. showed accelerated healing and re-
pair kinetics in young pig models of AMI reperfusion like
ours [67], which would limit the length of the experimen-
tal window. In addition, high intragroup variability and a
reduced number of animals per group are study limita-
tions, especially in the case of negative results.
The time of paMSC transplant also influences effect-
iveness; the optimal range varies from the time of AMI
to 1 week later, although a specific suitable time point
remains to be established [68]. Beneficial effects have
been reported following in vivo transfer of modified
MSC or recombinant factors from 1 week to 1 month
post-infarct induction. In addition, recent studies have
shown that a large proportion of the injected cells are
lost from the myocardium within the first few minutes
post-injection and not more than 0.1–15 % are retained.
Although positive therapeutic results are reported for
IGF-1- and HGF-expressing MSC individually, we con-
clude that co-administration of paMSC that overexpress
IGF-1 and HGF does not appear to have a synergistic ef-
fect or promote effective cardiac repair. This could be
caused by interference from high local levels of either
factor. The positive correlation of enhanced neovascular-
ization and fibrosis in a number of paMSC-IGF-1/HGF-
treated pigs suggests that sustained exposure to high
HGF + IGF-1 levels promotes both beneficial and deleteri-
ous effects, with no regenerative advantage. In any case,
global results strongly suggest that delivery of growth
factor by implantation of biodegradable microparticles
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in the affected area is superior to the transplant of
paMSC-mod cells that probably are not efficiently retained.
The consequence should be a much less efficient local
supply of growth factor, with reduced increment in a
therapeutic index. In addition, in case of a significant
therapeutic effect using modified MSC, it will be
mandatory to eliminate the possibility that non-retained
MSC could find other propitious niches and favor other
pathological conditions [69, 70].
Conclusions
Taken together, this study reports that co-administration
of IGF-1- and HGF-overexpressing paMSC do not promote
an effective repair, although we found an enhancement of
neovascularization and fibrosis in the paMSC-IGF-1/HGF-
treated group, suggesting that high IGF-1 + HGF levels
promote beneficial and deleterious effects that moderately
improves AMI recovery in a porcine model, although not
significantly.
Additional files
Additional file 1: Table S1. A list of the primer sequences used in this
work. (DOC 94 kb)
Additional file 2: Table S2. A list of the antibodies used in this work.
(DOC 104 kb)
Additional file 3: Figure S1. (A) Lentiviral vectors used for IGF-1 and
HGF forced expression in paMSC. (B) Fluorescence of cultures at distinct
viral concentrations after transduction with the pRRL-sin-IGF-1-IRES-GFP
vector. Images for paMSC-IGF-1-GFP, 5 days post-transduction, at distinct
multiplicity of infection (MOI, 1–50). (C) Cell sorting after paMSC transduction.
Four subpopulations resulting from sorting. Top panels, results for a
subpopulation cultured at 3 % O2; bottom, transduced paMSC cultured
in 20 % O2 conditions. An un-transduced cell population was used as a
negative control. Purity of sorted GFP-positive paMSC was 95 % and
91.1 % for cells cultured at 3 % and 20 % O2, respectively. (TIF 447 kb)
Additional file 4: Figure S2. Immunocytochemistry analysis of IGF-1
and HGF expression in paMSC-IGF- 1-GFP (A) and paMSC-HGF-Cherry (B).
(+) indicates cells transfected with pRRL-sin-IGF-1-IRES-GFP (A) or pRRL-
sin-HGF-IRES-Cherry vectors (B); (–) negative controls. GFP- (A-V) or
Cherry-positive cells (B-V) were tested for IGF-1 (A-Vi) or HGF (B-Vi)
expression; nuclei were DAPI stained (iii and Vii), showing that all paMSC-
IGF-1 and HGF were positive for GFP/Cherry and IGF-1/HGF, respectively,
and that paMSC-IGF-1 and HGF are negative for HGF and IGF-1, respectively.
HEK293T-derived populations were used as controls (A and B; upper panels);
controls confirm that HEK-293 do not express GFP/Cherry or IGF-1/HGF, and
that HEK293-IGF-1 and HEK293-HGF express GFP/Cherry and IGF-1/HGF,
respectively. Alexa 488- (green) and Alexa 568- (red) conjugated secondary
antibodies were used. Scale bars= 20 μm. (TIF 414 kb)
Additional file 5: Figure S3. Immunocytochemistry analysis of IGF-1
and HGF expression post-sorting in negative populations. Post-sorting
immunocytochemistry for IGF-1 in GFP-negative population (A) and
Cherry-negative population (B). Images confirm that IGF-1-negative cells
do not express GFP/Cherry or IGF-1, and that HGF-negative cells do not
express GFP/Cherry but demonstrated basal HGF levels. (C) HGF expression
was monitored in paMSC-IGF-1-GFP populations (positive and negative).
Positive populations were negative for HGF expression but the negative
fraction showed basal HGF levels. (D) IGF-1 expression was monitored in
paMSC-HGF-Cherry (positive and negative); both were positive for IGF-1
expression showing basal levels for this growth factor. (+) corresponds to
primary and secondary antibodies ICC; (–) corresponds to ICC only with
secondary antibodies. Secondary antibodies were Alexa-conjugated as in
Additional file 4 (Figure S2). Scale bars = 20 μm. (TIF 242 kb)
Additional file 6: Figure S4. Evaluation of infarct area and cardiac
enzymes, comparing T1 vs T2. (A) Infarct area estimation, T1 vs T2.
Analysis of (B) troponin I (TnI), (C) myoglobin (MYO) and (D) myocardial
creatine kinase (CKMB) of all groups confirmed porcine AMI; (*p ≤0.05).
(TIF 244 kb)
Additional file 7: Figure S5. (A) Immunohistocytochemistry analysis in
control animals (transplanted but not infarcted). Animal transplanted with
30 × 106 paMSC + GFP + SPIO cells. Left panels show negative controls,
incubation with Alexa 568-secondary antibody (top) and DAPI staining
(bottom). Center and right images show isolated GFP-positive cells (anti-
GFP-A568) in the Heart 2 section. (B) Immunohistocytochemistry analysis
of control animals (no treatment). Left and center images show negative
controls (DAPI staining and incubation with Alexa 568-secondary antibody).
Right image shows negative results for GFP immunofluorescence.
(TIF 1493 kb)
Additional file 8: Figure S6. Anti-GFP immunohistocytochemistry. (A)
GFP-positive paMSC in a representative animal of group III (paMSC-IGF- 1-
GFP/paMSC-HGF-Cherry). Bottom panel show serial cardiac sections
(5 μm) counterstained with DAPI (left), imaged for GFP fluorescence
(center) or anti-GFP-stained, and revealed with Cy3-streptavidin (right). Top
central image corresponds to the merge of the three images shown in
the bottom panel. Top left, negative control (group I) to determine tissue
autofluorescence, stained with DAPI and anti-GFP- biotin and revealed
with Cy3-streptavidin. Top right, an expanded view of the indicated
area in the left image. (B) Sections from Heart 4 samples from animals
representative of each group were stained with anti-GFP-biotin and
revealed with Cy3-streptavidin, and counterstained with DAPI. Left top,
control (group I); right top, transplanted uninfarcted animal; left bottom,
group II (paMSC-GFP+); and right bottom, group III (paMSC-IGF-1-GFP/
paMSC-HGF-Cherry) animals. (TIF 1592 kb)
Additional file 9: Figure S7. (A) Molecular analysis of cardiac tissue. At
1 month post-transplant, GFP-positive cells were monitored in cardiac tissue
(Heart 2) by genomic detection of GFP sequences (see Methods); ~100 bp
diagnostic fragment. ACTB (135-bp fragment) was used for normalization. (B)
Immunohistocytochemistry of anti-GFP with amplified FITC. Representative
sample (Heart 4) sections from an animal transplanted but not infarcted
were stained with anti-GFP-biotin and revealed with FITC-streptavidin, and
counterstained with DAPI. (TIF 664 kb)
Additional file 10: Figure S8. Histomorphological study of cardiac tissue
by Masson trichrome staining. Representative samples from each group,
showing fibrotic areas (light blue) resulting from AMI (IVS inter-ventricular
septum; LV left ventricle). (TIF 2164 kb)
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